Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.

Novartis AG is anticipating slow but steady uptake of Entresto (sacubitril/valsartan), its heart failure drug with blockbuster expectations that won an early nod from FDA.

Entresto, which combines the first-in-class neprilysin inhibitor sacubitril with the angiotensive II receptor blocker valsartan (Diovan), received FDA approval following...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.

US FDA Asking Questions About Commissioner’s Voucher Program With Details Scarce

 

FDA staff are trying to plan for program implementation in the absence of critical eligibility and other details, although guidance may be coming soon.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 

US FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.